RhumbLine Advisers’s Generate Biomedicines GENB Stock Holding History

RhumbLine Advisers’s Portfolio GENB Stock Details GENB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$517K	Buy	+30,648	New	+$418K	﹤0.01%	2747

Other funds holding GENB

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RhumbLine Advisers's GENB Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Generate Biomedicines (GENB) in Q2 2026: 30,648 shares worth $517K. The stake represents ﹤0.01% of the portfolio and ranks #2747 among its holdings.

86 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

RhumbLine Advisers held 30,648 shares of Generate Biomedicines worth $517K as of Q2 2026.
Generate Biomedicines was a new RhumbLine Advisers position in Q2 2026.
Generate Biomedicines made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2747 holding.
86 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.